Cargando…
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
BACKGROUND: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. OBJECTIVES: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with surgically unsalvageable giant cell tumor of bone. ME...
Autores principales: | Li, Shenglong, Chen, Peng, Yang, Qiankun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357891/ https://www.ncbi.nlm.nih.gov/pubmed/30740297 http://dx.doi.org/10.1016/j.jbo.2019.100217 |
Ejemplares similares
-
Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial
por: Yue, Jiaji, et al.
Publicado: (2022) -
Giant cell tumour of bone in os sacrum of a prepubertal girl – Surgical and medical treatment with zoledronate and denosumab
por: Beck-Nielsen, Signe Sparre, et al.
Publicado: (2023) -
The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
por: Zhang, Zhicai, et al.
Publicado: (2017) -
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab
por: Park, Jung-Wee
Publicado: (2021) -
Denosumab versus zoledronic acid for patients with beta-thalassemia major-induced osteoporosis
por: Yassin, Mohamed A., et al.
Publicado: (2020)